Ergebnis der Suchanfrage nach N&amp

Orte

Alle 12 Treffer anzeigenweniger anzeigen

Tampa Zams

Inhalte

Neueste Relevanteste

16.02.2018 – 17:01
Wirtschaft
Takeda Pharmaceutical Company Limited
Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFalpha-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease Patients in Comparative Effectiveness Real-World Data Analysis
Osaka, Japan (ots/PRNewswire) - New clinical study also provides data for Entyvio® in inducing complete mucosal healing and endoscopic remission, particularly in bio-naïve patients Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced new real-world data evaluating the comparative ...
mehr
01.02.2018 – 09:31
Wirtschaft
Novo Nordisk
Semaglutide Demonstrated Significant Reductions in Blood Sugar and Weight Compared with Dulaglutide; Results Published in The Lancet Diabetes & Endocrinology
Bagsværd, Denmark (ots/PRNewswire) - Results from the SUSTAIN 7 trial, which investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin, have been published in The Lancet Diabetes & Endocrinology.[1] ...
mehr
30.01.2018 – 06:01
Wirtschaft
GfK SE
Paris Continues its Reign as Highest-Rated City - GfK Data
Nuremberg, Germany (ots/PRNewswire) - - Sydney knocks New York off 3rd place, while Melbourne jumps from 9th to 7th - Tokyo records greatest score gain of all 50 cities The latest Anholt-GfK City Brands IndexSM (CBISM) reveals that Paris retains its position at the top. For the fourth time since the survey began, the global public regards Paris as the highest rated out of 50 cities. Australian cities also show ...
mehr
09.01.2018 – 07:01
Wirtschaft
UCB Pharma
CIMZIA® (certolizumab pegol) Label Change Marks Important Advance for European Women of Childbearing Age With Chronic Rheumatic Disease
Brussels (ots/PRNewswire) - - European Medicines Agency (EMA) has approved label change for UCB's CIMZIA® (certolizumab pegol), making it the first anti-TNF for potential use in women with chronic rheumatic disease, during both pregnancy and breastfeeding - Data submitted to regulatory authorities included ...
mehr
12.12.2017 – 13:53
Wirtschaft
Daiichi Sankyo Europe GmbH
Once-Daily, Oral LIXIANA® (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
Munich (ots/PRNewswire) - For EU media only - not for US journalists - Hokusai-VTE CANCER study is a phase 3b, prospective, randomised, open-label, blind end-point (PROBE) study evaluating edoxaban versus low molecular weight heparin (LMWH) dalteparin in venous thromboembolism (VTE) associated with primarily active ...
mehr
11.12.2017 – 09:02
Wirtschaft
Novo Nordisk
Xultophy® Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting
Bagsværd, Denmark (ots/PRNewswire) - - Results published in Diabetes, Obesity and Metabolism Newly published data from real-world European clinical practice has shown that Xultophy® (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study ...
mehr

07.12.2017 – 09:47
Wirtschaft
Novo Nordisk
Ryzodeg® Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan
Abu Dhabi, Uae (ots/PRNewswire) - In people with type 2 diabetes who fast during Ramadan, Ryzodeg® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate of nocturnal hypoglycaemia by 74% versus biphasic insulin aspart 30 (BIAsp 30 ...
mehr
07.12.2017 – 09:46
Wirtschaft
Novo Nordisk
Tresiba® Reduces Hypoglycaemia Regardless of Blood Sugar Level
Abu Dhabi, Uae (ots/PRNewswire) - People with either type 1 or type 2 diabetes treated with Tresiba® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets.[1] These new post-hoc analyses from the SWITCH 1 and 2 trials were presented at the International Diabetes Federation (IDF) Annual Congress in Abu Dhabi ...
mehr
05.12.2017 – 10:02
Wirtschaft
Novo Nordisk
Switching to Tresiba® Benefits People with Diabetes Irrespective of Blood Sugar Levels in a Real-world Setting
Bagsværd, Denmark (ots/PRNewswire) - - Switching to Tresiba® reduced the rate of hypoglycaemia by 67% in people with controlled blood sugar levels - In people with diabetes whose blood sugar was too high, switching to Tresiba® significantly improved blood sugar levels Switching to Tresiba® from another basal ...
mehr
28.11.2017 – 14:00
Gesundheit / Medizin
Debiopharm International SA
GenePOC Launches its GenePOC(TM) CDiff test in the United States / GenePOC announces the launch and FDA clearance of its Clostridium difficile molecular test in US
Québec, Canada (ots) - GenePOC Inc. (GenePOC), a member of the Debiopharm Group(TM), is proud to announce the launch of its 2nd FDA cleared assay in less than 6 months, GenePOC(TM) CDiff, for use on the revogene(TM) instrument. The GenePOC CDiff test targets the toxin B gene of toxigenic C. difficile strains in ...
mehr
28.11.2017 – 09:03
Wirtschaft
Bibby Offshore
Bibby Offshore Reaches Agreement With 80% of its Noteholders to Recapitalise the Business and Strengthen its Financial Position
Aberdeen, Scotland (ots/PRNewswire) - Bibby Offshore Holdings Limited ("Bibby Offshore" or the "Group"), is delighted to announce that it has reached a comprehensive agreement on the recapitalisation of its balance sheet with noteholders who hold 80% of the £175 million 7.5% senior secured notes due 15 June 2021 ...
mehr
22.11.2017 – 18:03
Wirtschaft
Highlight Communications AG
DGAP-News: 3Q2017: Highlight Group remains on track after nine months
DGAP-News: Highlight Communications AG / Key word(s): 9-month figures 3Q2017: Highlight Group remains on track after nine months 22.11.2017 / 18:00 The issuer is solely responsible for the content of this announcement. 631933 22.11.2017 ...
mehr

15.11.2017 – 11:20
Wirtschaft
World Innovation Summit for Education (WISE)
WISE Prize for Education 2017 Presented to Patrick Awuah, Founder of Ashesi University College, Ghana
Doha, Qatar (ots/PRNewswire) - The prestigious WISE Prize for Education has been presented to Mr Patrick Awuah, founder and president of Ashesi University College, a private, not-for-profit institution that has become one of Ghana's premier universities in little over a decade. Her Highness Sheikha Moza bint Nasser, ...
mehr
07.11.2017 – 20:07
Wirtschaft
Janssen EMEA
STELARA® (ustekinumab) Shows Positive Results in Treatment of Systemic Lupus Erythematosus in Phase 2 Trial
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY - 60% of patients receiving ustekinumab showed significant reductions in lupus disease activity vs. 31% of patients receiving placebo - Ustekinumab showed significant improvements in various disease measures compared with placebo, including ...
mehr
07.11.2017 – 20:06
Wirtschaft
Janssen EMEA
New Phase 2 Data Show Treatment With TREMFYA® (guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY Longer-term results demonstrate continued efficacy of anti-interleukin 23 monoclonal antibody guselkumab in improving joint and skin symptoms associated with active psoriatic arthritis Janssen Research & Development, LLC (Janssen) announced today ...
mehr
07.11.2017 – 14:01
Wirtschaft
Janssen EMEA
New Phase 2 Data Show Treatment With TREMFYA® (guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY Longer-term results demonstrate continued efficacy of anti-interleukin 23 monoclonal antibody guselkumab in improving joint and skin symptoms associated with active psoriatic arthritis Janssen Research & Development, LLC (Janssen) announced today ...
mehr
07.11.2017 – 10:45
Wirtschaft
Janssen EMEA
STELARA® (ustekinumab) Shows Positive Results in Treatment of Systemic Lupus Erythematosus in Phase 2 Trial
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY - 60% of patients receiving ustekinumab showed significant reductions in lupus disease activity vs. 31% of patients receiving placebo - Ustekinumab showed significant improvements in various disease measures compared with placebo, including ...
mehr
06.11.2017 – 17:01
Wirtschaft
GlaxoSmithKline Plc (GSK)
New GSK Multi-country Survey Reveals Need for Improved Awareness Around Long-term Impact and Appropriate use of Corticosteroids in SLE Management
San Diego and London (ots/PRNewswire) - Findings from a new multi-country GSK survey, released today to coincide with the 2017 American College of Rheumatology/Association for Rheumatology Health Professionals Annual Meeting (ACR/AHRP), reveal that patients with systemic lupus erythematosus (SLE) often self-manage ...
mehr

06.11.2017 – 09:56
Wirtschaft
Novo Nordisk
Switching to Tresiba® is Highly Cost-effective and Cost-saving in a Real-world Setting
Glasgow, Scotland (ots/PRNewswire) - Poster Presentation PDB27 A new analysis of real-world data has shown that switching to Tresiba® (insulin degludec) is highly cost-effective and cost-saving for the treatment of type 1 and type 2 diabetes, respectively.[1] The analysis was presented today at the International Society for Pharmacoeconomics and Outcomes Research ...
mehr
31.10.2017 – 13:02
Wirtschaft
Novo Nordisk
New US Study Reveals Key Reasons why Millions of People with Obesity are not Receiving Adequate Care
Washington (ots/PRNewswire) - Despite increasing recognition of obesity as a disease, many barriers to effective care remain Few of the more than 90 million Americans with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment In Obesity Management ...
mehr
19.10.2017 – 12:12
Wirtschaft
Teva Pharmaceutical Industries Ltd.
New Belief-based Patient Support Programme (PSP) Launched for People With Relapsing Multiple Sclerosis
Amsterdam (ots/PRNewswire) - Advanced MS Care Programme will offer tailored support for MS patients People living with relapsing forms of Multiple Sclerosis (MS) can now access a new Patient Support Programme (PSP) that offers tailored help based on their individual beliefs and support needs. Officially announced ...
mehr
18.10.2017 – 12:36
Wirtschaft
Merck Healthcare Germany
Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017
Darmstadt, Germany (ots/PRNewswire) - Not intended for US/UK based media Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017 - Important safety and immune cell analyses further characterize the selective immune reconstitution approach of Mavenclad - Continued innovation with Rebif includes analysis of NEDA and use of MAGNIMS ...
mehr
03.10.2017 – 14:00
Gesundheit / Medizin
Debiopharm International SA
Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur(TM), Triptorelin 6-month Formulation, for Treatment of Central Precocious Puberty (CPP)
Atlanta, GA, USA and Lausanne, Switzerland (ots) - Triptodur(TM), (triptorelin) extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty associated with CPP via a once every six-month intramuscular (IM) injection. Arbor Pharmaceuticals, LLC, a U.S. based specialty ...
mehr
03.10.2017 – 12:12
Wirtschaft
World Innovation Summit for Education (WISE)
WISE Accelerator 2017-18 Cohort Announced
Doha, Qatar (ots/PRNewswire) - Four promising edtech initiatives from France, Lebanon and UK selected by World Innovation Summit for Education (WISE) The World Innovation Summit for Education (WISE), a leading international initiative driving innovation and collaboration in education, has revealed the names of the four projects selected to benefit from the 2017-18 WISE Accelerator program. The selected 2017-18 WISE ...
mehr

03.10.2017 – 12:11
Wirtschaft
World Innovation Summit for Education (WISE)
WISE Accelerator 2017-18 Cohort Announced
Doha, Qatar (ots/PRNewswire) - Four promising edtech initiatives from France, Lebanon and UK selected by World Innovation Summit for Education (WISE) The World Innovation Summit for Education (WISE), a leading international initiative driving innovation and collaboration in education, has revealed the names of the four projects selected to benefit from the 2017-18 WISE Accelerator program. The selected 2017-18 WISE ...
mehr
27.09.2017 – 10:04
Wirtschaft
Merck Healthcare Germany
Bavencio (avelumab) Approved for Merkel Cell Carcinoma in Japan
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First-ever treatment indicated for curatively unresectable Merkel cell carcinoma (MCC) and first anti-PD-L1 to be available in Japan - Japanese Ministry of Health, Labour and Welfare (MHLW) decision based on Javelin Merkel 200 study, the largest registrational trial for an immunotherapy in MCC - First Asian approval for ...
mehr
26.09.2017 – 11:01
Wirtschaft
World Innovation Summit for Education (WISE)
Six Winners of the 2017 Wise Awards Announced
Doha, Qatar (ots/PRNewswire) - The WISE Awards Recognize Projects for Innovative Solutions to Urgent Education Challenges The World Innovation Summit for Education (WISE), a leading international initiative for innovation and collaboration in education, has named the six winning projects of the 2017 WISE Awards, recognizing and promoting innovative education initiatives around the world. The 2017 WISE Awards winners: 42 ...
mehr
21.09.2017 – 09:13
Wirtschaft
Merck Healthcare Germany
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Darmstadt, Germany, and New York, Usa (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK - Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland - Approval is based on ...
mehr
15.09.2017 – 09:32
Wirtschaft
Novo Nordisk
Tresiba® Trial Shows that People with Type 2 Diabetes who Avoid Severe Hypoglycaemia have a Reduced Risk of Death
Lisbon, Portugal (ots/PRNewswire) - Symposium: S33 Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia (low blood sugar levels) are at greater risk of death. The risk was four-fold higher 15 days ...
mehr
12.09.2017 – 10:05
Wirtschaft
Teva Pharmaceuticals Europe BV
Teva Presents First Real-World Evidence Demonstrating Treatment with DuoResp Spiromax® Inhaler was Comparable to Symbicort Turbuhaler®
Amsterdam (ots/PRNewswire) - ONLY FOR PAN-EUROPEAN/ EUROPEAN ENGLISH LANGUAGE MEDICAL TRADE MEDIA Study Highlights Improved Outcomes for Asthma Patients Including Fewer Exacerbations Following Change in Treatment to DuoResp Spiromax® Teva Pharmaceuticals Europe B.V., (NYSE and TASE: TEVA) today announced data from ...
mehr

Vorherige12345678910Nächste